Pilot Study Evaluating the Safety of Electroducer Sleeve Medical Device for Temporary Cardiac Stimulation During Percutaneous Cardiovascular Interventions, in All Kind of Patients

During percutaneous cardiovascular intervention, temporary cardiac stimulation may be required. Usually this stimulation is generated via a temporary pacing catheter. In order to reduce the complexity of the procedure, a new stimulation strategy has been developed: the "Direct Wire Pacing technique".In this approach, the cardiac stimulation is provided via the guidewire connected to an external pacemaker.

Previous study demonstrated the superiority of the new technique compared to the former. However this technique is likely to generate electrical pain, risk of bleeding for the patient and risk of blood exposure accident for the operators. This is why the medical device ELECTRODUCER SLEEVE has been developed. This device integrates a pacing function to the introducer and the guidewire used. The "Direct Wire Pacing technique" is simplified, secured and more reproducible.

Study Overview

• Status: Completed
• Conditions: Coronary Disease; Pacemaker DDD; Valve Heart Disease
• Intervention / Treatment: Device: Electroducer Sleeve

Detailed Description

During percutaneous cardiovascular interventions such as Transcatheter Heart Valve or coronary intervention, temporary cardiac stimulation may be required. Usually this stimulation is generated via a temporary pacing catheter in the right ventricle. This procedure requires an additional venous access and the insertion of the stimulation catheter, which are both likely to generate complications. In order to reduce the complexity and increase the safety of the procedure, a new stimulation strategy has been developed: the "Direct Wire Pacing technique". In this approach, the specific venous access and the implantation of a stimulation catheter are avoided. The cardiac stimulation is provided via the guidewire inserted into the left ventricle or into the coronary arteries. This guidewire is connected to an external Pacemaker using an alligator clamp (Cathode). The Pacemaker anode is also connected using a clamp attached to a needle piercing the subcutaneous tissue, obtaining a closed electrical circuit. This technique was validated during previous studies in the TAVI context through two registries and one randomized controlled trial. This study demonstrated the superiority of the new technique by showing a reduction of the procedural duration, radiation exposure and costs; with similar efficacy and safety. However the subcutaneous needle insertion is likely to generate electrical pain, risk of bleeding for the patient and risk of blood exposure accident for the operators. This subcutaneous anode increases the stimulation threshold (mA) which can cause stimulation failures. Moreover, several technical difficulties preclude general adoption by the scientific community. This is why the medical device ELECTRODUCER SLEEVE has been developed. This device integrates a pacing function to the introducer and the guidewire used during percutaneous cardiovascular interventions. The guidewire then behaves like an intra-cardiac cathode. Thanks to the device, the complex manipulation of needles and clamps during the intervention are avoided as well as pole inversions. The "Direct Wire Pacing technique" used during the coronary and structural interventions is thus simplified, secured and more reproducible.

• Study Type: Interventional
• Enrollment (Actual): 60
• Phase: Not Applicable

Contacts and Locations

Study Locations

• France
  • Grenoble, France
    • GHMG

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 99 years (ADULT, OLDER_ADULT)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients ≥ 18 years old
• Patients with a percutaneous cardiovascular intervention indication, requiring temporary cardiac stimulation
• Procedure carried out with a 6Fr TERUMO introducer ≥ 65 mm
• Procedure performed by femoral or radial routes
• Patients able to understand and provide informed consent
• Patients able to perform the planned follow-up visit one month after the procedure.

Exclusion Criteria:

• Patients requiring a definitive PM
• Pregnant or breastfeeding woman
• Patiens under judicial protection, tutorship or curatorship
• Negative Allen test or absence of radial pulse in the artery or vein used for intervention
• Patient participating in another interventional clinical trial.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: OTHER
• Allocation: NON_RANDOMIZED
• Interventional Model: PARALLEL
• Masking: NONE

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
EXPERIMENTAL: Radial group; Use of Electroducer Sleeve on radial route	Device: Electroducer Sleeve; The device's safety will be assessed at the radial and femoral puncture site
EXPERIMENTAL: femoral group; Use of Electroducer Sleeve on femoral route	Device: Electroducer Sleeve; The device's safety will be assessed at the radial and femoral puncture site

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To assess the peri procedural safety of ELECTRODUCER SLEEVE device used for temporary cardiac pacing during percutaneous cardiovascular interventions, by radial and femoral routes of access.	The device safety is assessed through the occurrence of bleeding complications at the access site where the ELECTRODUCER SLEEVE was used, including: Hematoma formation (EASY Classification) and Access-site Bleeding (BARC classification).	during intervention

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
To evaluate the occurrence of Radial Artery Occlusion	RAO evaluated by a radial artery Doppler and by a reverse Allen test	at discharge and 1 month
To evaluate the occurrence of allergic or adverse tissue reactions	Outcome evaluated through the clinical examination of the puncture site.	at discharge and 1 month
To establish the efficacy of the ELECTRODUCER SLEEVE device	Outcome evaluated through the capture in the surface electrocardiogram : each spike delivered on the guidewire is follow by its hemodynamic effect.	during intervention
To evaluate the performance of the ELECTRODUCER SLEEVE device	Performance evaluated through the stimulation threshold (mA) measured with the external pacemaker	during intervention
To evaluate the impact of the ELECTRODUCER SLEEVE use on the TAVI procedure duration.	Procedure duration is defined between the first vascular puncture and the last introducer removal and compared to the EASY TAVI study data	during intervention
To evaluate the patient comfort with ELECTRODUCER SLEEVE use	Confort evaluated using the "Echelle Visuelle Analogique de la douleur" from 0 to 10: 0 being the absence of pain and 10 being unbearable pain.	during intervention
To assess the user's overall impression of the ELECTRODUCER SLEEVE device and use.	Outcome evaluated by a satisfaction questionnaire developed by Electroducer, composed of four questions and a free comment section.	during intervention

Collaborators and Investigators

• Sponsor: Electroducer

Study record dates

Study Major Dates

• Study Start (ACTUAL): July 28, 2020
• Primary Completion (ACTUAL): January 25, 2021
• Study Completion (ACTUAL): February 22, 2021

Study Registration Dates

• First Submitted: April 28, 2020
• First Submitted That Met QC Criteria: April 30, 2020
• First Posted (ACTUAL): May 4, 2020

Study Record Updates

• Last Update Posted (ACTUAL): March 1, 2021
• Last Update Submitted That Met QC Criteria: February 26, 2021
• Last Verified: October 1, 2020

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Myocardial Ischemia; Cardiovascular Diseases; Vascular Diseases; Heart Diseases; Coronary Disease; Heart Valve Diseases
• Other Study ID Numbers: Electroducer study

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No